Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits.
Target CD33 / FLT3 (protective antigen EMCN on healthy HSCs)
Indications
Relapsed/refractory hematologic malignancies, including AML (CD33 and/or FLT3 positive)(Phase 1)
Status note Phase 1 ongoing (US and Australia); IND cleared Dec 2023. Orphan Drug Designation Jun 2025; RMAT designation Dec 2025. Jul 2026 merger: affiliate of Celadon Partners acquires substantially all business/pipeline; SENTI-202 continues under Parent with up to $60M CVRs to Senti stockholders on BLA filing/approval/$200M sales milestones.
Status note Early-stage program retained by the public company under the merger agreement.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
—
Hepatocellular Carcinoma (HCC)
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.